SPOTLIGHT: Exelixis gains $35M milestone payment from GSK


GSK has exercised its option to exclusively license Exelixis' XL880 for further development. Exelixis gains a milestone payment of $35 million, as well as additional payments upon the attainment of specific development and commercialization milestones. Release